caffeine has been researched along with Panic Disorder in 32 studies
Panic Disorder: A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A subgroup of patients with Panic Disorder (PD) exhibits increased sensitivity to caffeine administration." | 9.20 | Lack of specific association between panicogenic properties of caffeine and HPA-axis activation. A placebo-controlled study of caffeine challenge in patients with panic disorder. ( Markianos, M; Masdrakis, VG; Oulis, P, 2015) |
| " Our aim was to observe if panic disorder (PD) patients and generalized social anxiety disorder (GSAD) and performance social anxiety disorder (PSAD) patients respond in a similar way to the induction of anxiety symptoms and panic attacks by an oral caffeine challenge test." | 9.14 | Panic disorder and social anxiety disorder subtypes in a caffeine challenge test. ( Araújo, DM; de-Melo-Neto, VL; Freire, RC; King, AL; Lopes, FL; Mezzasalma, MA; Nardi, AE; Nascimento, I; Rassi, A; Soares-Filho, GL; Valença, AM; Veras, AB; Zin, WA, 2009) |
| "Our aim was to observe the induction of anxiety symptoms and panic attacks by a caffeine challenge test in panic disorder (PD) patients (DSM-IV) and their healthy first-degree relatives." | 9.13 | A caffeine challenge test in panic disorder patients, their healthy first-degree relatives, and healthy controls. ( de-Melo-Neto, VL; Freire, RC; King, AL; Lopes, FL; Mezzasalma, MA; Nardi, AE; Nascimento, I; Rassi, A; Soares-Filho, GL; Valença, AM; Veras, AB; Zin, WA, 2008) |
| "Our aim was to compare the demographic and clinical features of panic disorder (PD) patients with agoraphobia-DSM-IV-who had a panic attack after both an oral caffeine and the 35% carbon dioxide (CO2) challenge tests (responsive group) and compare them with PD patients who did not have a panic attack after both tests (non-responsive group)." | 9.12 | Caffeine and 35% carbon dioxide challenge tests in panic disorder. ( de-Melo-Neto, VL; Freire, RC; King, AL; Lopes, FL; Mezzasalma, MA; Nardi, AE; Nascimento, I; Soares-Filho, GL; Valença, AM; Veras, AB; Zin, WA, 2007) |
| "The effects on measures of anxiety from two doses of oral caffeine (250 and 500 mg) and placebo were compared in 12 patients with generalized anxiety disorder (GAD), 12 patients with panic disorder, and 12 normal subjects." | 9.07 | Anxiogenic effects of caffeine in patients with anxiety disorders. ( Bruce, M; Lader, M; Scott, N; Shine, P, 1992) |
| "It has been demonstrated that patients with panic disorder are more sensitive than normal control subjects to the anxiogenic effects of caffeine." | 9.07 | Quantitative electroencephalographic effects of caffeine in panic disorder. ( Coppola, R; Newman, F; Stein, MB; Trettau, JR; Uhde, TW, 1992) |
| "The behavioral and neuroendocrine effects of meta-chlorophenylpiperazine (m-CPP), a serotonergic agonist, were compared with the effects of caffeine, an adenosine antagonist, in panic disorder patients." | 9.07 | Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. ( Geraci, MF; Klein, E; Murphy, DL; Uhde, TW; Zohar, J, 1991) |
| "This systematic review aimed to examine the results of studies that have investigated the induction of panic attacks and/or the anxiogenic effect of the caffeine challenge test in patients with panic disorder." | 8.87 | Caffeine challenge test and panic disorder: a systematic literature review. ( Nardi, AE; Rocha Araujo, DM; Vilarim, MM, 2011) |
| " Previously we demonstrated that panic disorder patients have blunted growth hormone (GH) responses to clonidine, an alpha 2-adrenergic agonist." | 8.78 | Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. ( Black, B; Boulenger, JP; Geraci, M; Gurguis, G; Post, RM; Roscow, DB; Rubinow, DR; Tancer, ME; Uhde, TW; Vittone, B, 1992) |
| " In patients with Panic Disorder (PD), lower baseline BH duration is associated with caffeine-induced panic attacks." | 7.75 | Caffeine challenge and breath-holding duration in patients with panic disorder. ( Markianos, M; Masdrakis, VG; Oulis, P; Papakostas, YG; Vaidakis, N, 2009) |
| "A proportion of patients with panic disorder (PD) display an increased sensitivity to the anxiogenic/panicogenic properties of caffeine." | 7.74 | Caffeine challenge in patients with panic disorder: baseline differences between those who panic and those who do not. ( Masdrakis, VG; Papageorgiou, C; Papakostas, YG; Pehlivanidis, A; Vaidakis, N, 2008) |
| "A subgroup of patients with Panic Disorder (PD) exhibits increased sensitivity to caffeine administration." | 5.20 | Lack of specific association between panicogenic properties of caffeine and HPA-axis activation. A placebo-controlled study of caffeine challenge in patients with panic disorder. ( Markianos, M; Masdrakis, VG; Oulis, P, 2015) |
| " Our aim was to observe if panic disorder (PD) patients and generalized social anxiety disorder (GSAD) and performance social anxiety disorder (PSAD) patients respond in a similar way to the induction of anxiety symptoms and panic attacks by an oral caffeine challenge test." | 5.14 | Panic disorder and social anxiety disorder subtypes in a caffeine challenge test. ( Araújo, DM; de-Melo-Neto, VL; Freire, RC; King, AL; Lopes, FL; Mezzasalma, MA; Nardi, AE; Nascimento, I; Rassi, A; Soares-Filho, GL; Valença, AM; Veras, AB; Zin, WA, 2009) |
| "Our aim was to observe the induction of anxiety symptoms and panic attacks by a caffeine challenge test in panic disorder (PD) patients (DSM-IV) and their healthy first-degree relatives." | 5.13 | A caffeine challenge test in panic disorder patients, their healthy first-degree relatives, and healthy controls. ( de-Melo-Neto, VL; Freire, RC; King, AL; Lopes, FL; Mezzasalma, MA; Nardi, AE; Nascimento, I; Rassi, A; Soares-Filho, GL; Valença, AM; Veras, AB; Zin, WA, 2008) |
| "Our aim was to compare the demographic and clinical features of panic disorder (PD) patients with agoraphobia-DSM-IV-who had a panic attack after both an oral caffeine and the 35% carbon dioxide (CO2) challenge tests (responsive group) and compare them with PD patients who did not have a panic attack after both tests (non-responsive group)." | 5.12 | Caffeine and 35% carbon dioxide challenge tests in panic disorder. ( de-Melo-Neto, VL; Freire, RC; King, AL; Lopes, FL; Mezzasalma, MA; Nardi, AE; Nascimento, I; Soares-Filho, GL; Valença, AM; Veras, AB; Zin, WA, 2007) |
| " Panicogenic doses of caffeine were administered to 8 panic disorder (PD) patients and 11 healthy volunteers during stage 3-4 sleep, when cognitive processing is minimal and the threshold to external stimuli is high." | 5.08 | Can panic be induced in deep sleep? Examining the necessity of cognitive processing for panic. ( Ferro, D; Koenigsberg, HW; Pollak, CP, 1998) |
| "The effects on measures of anxiety from two doses of oral caffeine (250 and 500 mg) and placebo were compared in 12 patients with generalized anxiety disorder (GAD), 12 patients with panic disorder, and 12 normal subjects." | 5.07 | Anxiogenic effects of caffeine in patients with anxiety disorders. ( Bruce, M; Lader, M; Scott, N; Shine, P, 1992) |
| "It has been demonstrated that patients with panic disorder are more sensitive than normal control subjects to the anxiogenic effects of caffeine." | 5.07 | Quantitative electroencephalographic effects of caffeine in panic disorder. ( Coppola, R; Newman, F; Stein, MB; Trettau, JR; Uhde, TW, 1992) |
| "The behavioral and neuroendocrine effects of meta-chlorophenylpiperazine (m-CPP), a serotonergic agonist, were compared with the effects of caffeine, an adenosine antagonist, in panic disorder patients." | 5.07 | Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects. ( Geraci, MF; Klein, E; Murphy, DL; Uhde, TW; Zohar, J, 1991) |
| "This systematic review aimed to examine the results of studies that have investigated the induction of panic attacks and/or the anxiogenic effect of the caffeine challenge test in patients with panic disorder." | 4.87 | Caffeine challenge test and panic disorder: a systematic literature review. ( Nardi, AE; Rocha Araujo, DM; Vilarim, MM, 2011) |
| "Various provocative agents, including sodium lactate, carbon dioxide (CO2), caffeine, yohimbine, serotoninergic agents, and cholecystokinin (CCK), have been utilized as panicogenics in studies on healthy volunteers as well as in panic disorder patients." | 4.80 | Neurobiology of panic disorder. ( Baker, GB; Bourin, M; Bradwejn, J, 1998) |
| " Challenge studies have demonstrated that subjects with social anxiety disorder have a sensitivity to carbon dioxide, cholecystokinin, and caffeine somewhere between that of panic disorder patients and normal controls." | 4.80 | Brain mechanisms of social anxiety disorder. ( Bell, CJ; Malizia, AL; Nutt, DJ, 1998) |
| "Various provocative agents, including sodium lactate, carbon dioxide (CO2), caffeine, yohimbine and cholecystokinin (CCK), have been utilized as panicogenics in studies on healthy volunteers as well as in panic disorder patients." | 4.79 | [From inducers of panic attack to neurobiology of panic disorder]. ( Bourin, M, 1996) |
| " Previously we demonstrated that panic disorder patients have blunted growth hormone (GH) responses to clonidine, an alpha 2-adrenergic agonist." | 4.78 | Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. ( Black, B; Boulenger, JP; Geraci, M; Gurguis, G; Post, RM; Roscow, DB; Rubinow, DR; Tancer, ME; Uhde, TW; Vittone, B, 1992) |
| " In patients with Panic Disorder (PD), lower baseline BH duration is associated with caffeine-induced panic attacks." | 3.75 | Caffeine challenge and breath-holding duration in patients with panic disorder. ( Markianos, M; Masdrakis, VG; Oulis, P; Papakostas, YG; Vaidakis, N, 2009) |
| "A proportion of patients with panic disorder (PD) display an increased sensitivity to the anxiogenic/panicogenic properties of caffeine." | 3.74 | Caffeine challenge in patients with panic disorder: baseline differences between those who panic and those who do not. ( Masdrakis, VG; Papageorgiou, C; Papakostas, YG; Pehlivanidis, A; Vaidakis, N, 2008) |
| " Helping the client alter her caffeine intake and dietary habits led to a significant reduction in panic attacks, but had less impact on her anxiety levels and sense of control." | 3.69 | Somatic sensations, anxiety, and control in panic disorder. ( Berenbaum, H; Salzer, MS, 1994) |
| "GAD, phobias, and MDD shared genetic factors with caffeine use, with genetic correlations estimated to be 0." | 1.38 | Common psychiatric disorders and caffeine use, tolerance, and withdrawal: an examination of shared genetic and environmental effects. ( Bergin, JE; Kendler, KS, 2012) |
| " Combined, chronic administration of these doses yielded a sustained synergism in motor performance impairment, which contrasted with the antagonism usually found between the benzodiazepines and methylxanthines when performance is evaluated by psychomotor tests not requiring fine motor control." | 1.28 | Sustained synergism by chronic caffeine of the motor control deficit produced by midazolam. ( Falk, JL; Lau, CE, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (62.50) | 18.2507 |
| 2000's | 9 (28.13) | 29.6817 |
| 2010's | 3 (9.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Masdrakis, VG | 4 |
| Markianos, M | 2 |
| Oulis, P | 2 |
| Vaidakis, N | 3 |
| Papakostas, YG | 3 |
| Nardi, AE | 4 |
| Lopes, FL | 3 |
| Freire, RC | 3 |
| Veras, AB | 3 |
| Nascimento, I | 3 |
| Valença, AM | 3 |
| de-Melo-Neto, VL | 3 |
| Soares-Filho, GL | 3 |
| King, AL | 3 |
| Araújo, DM | 1 |
| Mezzasalma, MA | 3 |
| Rassi, A | 2 |
| Zin, WA | 3 |
| Vilarim, MM | 1 |
| Rocha Araujo, DM | 1 |
| Bergin, JE | 1 |
| Kendler, KS | 1 |
| Ströhle, A | 1 |
| Sahún, I | 1 |
| Gallego, X | 1 |
| Gratacòs, M | 1 |
| Murtra, P | 1 |
| Trullás, R | 1 |
| Maldonado, R | 1 |
| Estivill, X | 1 |
| Dierssen, M | 1 |
| Papageorgiou, C | 1 |
| Pehlivanidis, A | 1 |
| Legaki, EM | 1 |
| Ploumpidis, D | 1 |
| Soldatos, CR | 1 |
| Northcott, CJ | 1 |
| Stein, MB | 2 |
| Salzer, MS | 1 |
| Berenbaum, H | 1 |
| Tancer, ME | 3 |
| Apfeldorf, WJ | 1 |
| Shear, MK | 1 |
| Christensen, L | 1 |
| Bourgeois, A | 1 |
| Cockroft, R | 1 |
| Krystal, JH | 1 |
| Deutsch, DN | 1 |
| Charney, DS | 1 |
| Bourin, M | 2 |
| Baker, GB | 1 |
| Bradwejn, J | 1 |
| Nutt, DJ | 2 |
| Bell, CJ | 2 |
| Malizia, AL | 2 |
| Koenigsberg, HW | 1 |
| Pollak, CP | 1 |
| Ferro, D | 1 |
| Rothmann, C | 1 |
| Aussedat, M | 1 |
| Noizet, M | 1 |
| Weber, M | 1 |
| Pohl, R | 1 |
| Yeragani, VK | 1 |
| Balon, R | 1 |
| Lycaki, H | 1 |
| McBride, R | 1 |
| Bruce, M | 1 |
| Scott, N | 1 |
| Shine, P | 1 |
| Lader, M | 1 |
| Newman, F | 1 |
| Trettau, JR | 1 |
| Coppola, R | 1 |
| Uhde, TW | 4 |
| Nutt, D | 1 |
| Lawson, C | 1 |
| Rubinow, DR | 1 |
| Roscow, DB | 1 |
| Boulenger, JP | 1 |
| Vittone, B | 1 |
| Gurguis, G | 1 |
| Geraci, M | 1 |
| Black, B | 2 |
| Post, RM | 1 |
| Lau, CE | 1 |
| Falk, JL | 1 |
| Klein, E | 1 |
| Zohar, J | 1 |
| Geraci, MF | 1 |
| Murphy, DL | 1 |
| Brown, TM | 1 |
10 reviews available for caffeine and Panic Disorder
| Article | Year |
|---|---|
Caffeine challenge test and panic disorder: a systematic literature review.
Topics: Anxiety Disorders; Caffeine; Central Nervous System Stimulants; Diagnostic Techniques, Neurological; | 2011 |
[Experimental provocation of panic attacks as a human experimental model for anxiety].
Topics: Anxiety Disorders; Atrial Natriuretic Factor; Bicarbonates; Caffeine; Disease Models, Animal; Lactat | 2003 |
The biological basis of panic disorder.
Topics: Brain; Caffeine; Carbon Dioxide; gamma-Aminobutyric Acid; Humans; Lactates; Norepinephrine; Panic Di | 1996 |
[From inducers of panic attack to neurobiology of panic disorder].
Topics: Arousal; Brain; Caffeine; Carbon Dioxide; Cholecystokinin; Humans; Lactic Acid; Neurotransmitter Age | 1996 |
Neurobiology of panic disorder.
Topics: Caffeine; Carbon Dioxide; Cholecystokinin; Humans; Neurotransmitter Agents; Panic Disorder; Piperazi | 1998 |
Brain mechanisms of social anxiety disorder.
Topics: Animals; Brain; Caffeine; Carbon Dioxide; Cholecystokinin; Dopamine; Fear; Fenfluramine; Humans; Pan | 1998 |
The neurobiology of social phobia.
Topics: Brain; Caffeine; Carbon Dioxide; Cholecystokinin; Epinephrine; Female; Flumazenil; Human Growth Horm | 1999 |
Panic attacks. A neurochemical overview of models and mechanisms.
Topics: Bicarbonates; Caffeine; Female; Humans; Hypercapnia; Hyperventilation; Lactates; Lactic Acid; Male; | 1992 |
Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers.
Topics: Caffeine; Clonidine; Glucose; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Hypothalamus | 1992 |
Phenomenology and neurobiology of social phobia: comparison with panic disorder.
Topics: Adult; Age Factors; Caffeine; Dexamethasone; Diagnosis, Differential; Female; Humans; Lactates; Male | 1991 |
8 trials available for caffeine and Panic Disorder
| Article | Year |
|---|---|
Lack of specific association between panicogenic properties of caffeine and HPA-axis activation. A placebo-controlled study of caffeine challenge in patients with panic disorder.
Topics: Adrenocorticotropic Hormone; Adult; Arousal; Caffeine; Cross-Over Studies; Dehydroepiandrosterone Su | 2015 |
Panic disorder and social anxiety disorder subtypes in a caffeine challenge test.
Topics: Adolescent; Adult; Analysis of Variance; Caffeine; Central Nervous System Stimulants; Double-Blind M | 2009 |
Caffeine and 35% carbon dioxide challenge tests in panic disorder.
Topics: Adolescent; Adult; Age of Onset; Agoraphobia; Caffeine; Carbon Dioxide; Central Nervous System Stimu | 2007 |
A caffeine challenge test in panic disorder patients, their healthy first-degree relatives, and healthy controls.
Topics: Adult; Arousal; Caffeine; Central Nervous System Stimulants; Citrates; Double-Blind Method; Female; | 2008 |
Can panic be induced in deep sleep? Examining the necessity of cognitive processing for panic.
Topics: Adolescent; Adult; Caffeine; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Panic; Panic | 1998 |
Anxiogenic effects of caffeine in patients with anxiety disorders.
Topics: Alpha Rhythm; Anxiety Disorders; Blood Pressure; Caffeine; Diagnosis, Differential; Double-Blind Met | 1992 |
Quantitative electroencephalographic effects of caffeine in panic disorder.
Topics: Adult; Brain Mapping; Caffeine; Electroencephalography; Equipment Design; Female; Humans; Male; Pani | 1992 |
Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
Topics: Adult; Anxiety Disorders; Arousal; Brain; Caffeine; Double-Blind Method; Female; Humans; Hydrocortis | 1991 |
14 other studies available for caffeine and Panic Disorder
| Article | Year |
|---|---|
Caffeine challenge and breath-holding duration in patients with panic disorder.
Topics: Adult; Asphyxia; Caffeine; Carbon Dioxide; Female; Humans; Male; Panic Disorder; Respiration | 2009 |
Combination therapy for panic disorder. Recent analyses reinforce the view that adding psychotherapy to medication improves outcomes.
Topics: Antidepressive Agents; Benzodiazepines; Caffeine; Cognitive Behavioral Therapy; Combined Modality Th | 2008 |
Common psychiatric disorders and caffeine use, tolerance, and withdrawal: an examination of shared genetic and environmental effects.
Topics: Adult; Anorexia Nervosa; Anxiety Disorders; Bulimia; Caffeine; Depressive Disorder, Major; Diseases | 2012 |
Differential responses to anxiogenic drugs in a mouse model of panic disorder as revealed by Fos immunocytochemistry in specific areas of the fear circuitry.
Topics: Animals; Anxiety; Brain; Caffeine; Disease Models, Animal; Fear; Male; Mice; Mice, Transgenic; Oncog | 2007 |
Caffeine challenge in patients with panic disorder: baseline differences between those who panic and those who do not.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Diagnostic and Statistical Manual of Mental Diso | 2008 |
Auditory hallucinations during a caffeine challenge in a patient with panic disorder.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Hallucinations; Humans; Male; Panic Disorder; Ps | 2007 |
Panic disorder in pregnancy.
Topics: Adult; Breast Feeding; Caffeine; Female; Humans; Middle Aged; Panic Disorder; Parity; Pregnancy; Pre | 1994 |
Somatic sensations, anxiety, and control in panic disorder.
Topics: Adult; Agoraphobia; Anxiety; Arousal; Behavior Therapy; Caffeine; Combined Modality Therapy; Feeding | 1994 |
Neurobiology of social phobia.
Topics: Animals; Caffeine; Depressive Disorder; Dexamethasone; Diagnosis, Differential; Dogs; Epinephrine; H | 1993 |
Caffeine potentiation of taste in panic-disorder patients.
Topics: Adult; Agoraphobia; Caffeine; Drug Synergism; Female; Humans; Male; Middle Aged; Panic Disorder; Qui | 1993 |
Electroencephalographic concomitants of a caffeine-induced panic reaction.
Topics: Adult; Brain; Caffeine; Drinking; Electroencephalography; Female; Functional Laterality; Humans; Pan | 1993 |
[Subcutaneous caffeine intoxication].
Topics: Adolescent; Caffeine; Female; Humans; Injections, Subcutaneous; Panic Disorder; Poisoning | 1999 |
Smoking in patients with panic disorder.
Topics: Adult; Age Factors; Caffeine; Cross-Sectional Studies; Female; Humans; Incidence; Male; Michigan; Pa | 1992 |
Sustained synergism by chronic caffeine of the motor control deficit produced by midazolam.
Topics: Animals; Caffeine; Discrimination Learning; Drug Synergism; Male; Midazolam; Panic Disorder; Psychom | 1991 |